The anemia of end-stage renal disease: Hematopoietic progenitor cell response. Patients with the anemia of end-stage renal disease (ESRD) fail to display an appropriate compensatory increase in red cell production. In order to investigate the extent to which the impaired erythropoietic response is determined at the progenitor cell level, we determined the frequencies of marrow colony-forming cells in II anemic and 3 non-anemic, dialysis-dependent ESRD patients and 10 healthy individuals. In addition, we measured serum levels of erythropoietin (Epo) by radioimmunoassay. There were no significant differences (P > 0.1) between normal and ESRD groups in the frequencies of primitive or late erythroid (BFU-E and CFU-E, respectively), granulocyte-macrophage. and megakaryocyte progenitors, CFU-E/BFU-E ratios, or serum Epa levels. In contrast, 5 non-uremic patients with chronic anemia comparable in severity to the anemic ESRD patients had serum Epo levels and CFU-E/BFU-E ratios that were significantly increased (P < 0.05 and P <0.001, respectively) in comparison to the normal controls and ESRD patients. Pre-dialysis serum and plasma from both ESRD groups were as supportive of autologous erythroid and non-erythroid colony growth in vitro as normal serum and plasma; inhibition was not observed. We conclude that the relative numbers of erythroid and non-erythroid progenitors and the majority of serum Epo levels are unchanged from normal in patients with the anemia of ESRD. However, their normal CFU-E/BFtJ-E ratio reflects an inadequate compensatory erythropoietic response due to their inability to appropriately increase Epa production in response to anemia. Inhibitors of autologous erythroid colony formation were not detected in ESRI) serum. Proof of the pathogenetic significance of retained inhibitors of erythroid marrow function in ESRD will likely require in viva studies which directly compare the acute responses of normal individuals and anemic ESRD patients to graded doses of infused Epo. performed with informed consent under a protocol approved by the Human Subjects Review Committee of the University of Washington.
Patients with end-stage renal disease (ESRD) are usually anemic and fail to display an appropriate compensatory erythropoietic response to the anemia [I, 2] . It is generally accepted that impaired renal production of erythropoietin (Epo) is the primary cause of this blunted marrow response [3, 4] . In addition, some workers have speculated, on the basis of in vitro studies and indirect clinical evidence, that retained inhibitors of erythroid marrow function may contribute to the anemia of ESRD [5] .
In this study, we have measured serum Epo levels and marrow colony-forming cell frequencies in a group of anemic ESRD patients and compared these results to the values observed in non-anemic ESRD patients, healthy controls, and a group of anemic patients with appropriate marrow responses.
We sought to investigate the extent to which the impaired erythropoietic response in anemic ESRD patients is reflected at the progenitor cell level. In order to evaluate the potential significance of retained inhibitors in these patients, we also have examined the effect of their serum and plasma on erythroid and non-erythroid colony growth in cultures of autologous marrow cells.
Methods

Study population
The subjects with ESRD evaluated in these studies included 11 patients with chronic anemia (hematocrit 15 to 26%, predialysis serum creatinine 9.6 to 20.8 mg/dl) and 3 patients who were not anemic (hematocrit 42 to 43%, pre-dialysis serum creatinine 11.8 to 17.8 mgldl). All of these patients were hemodialysis-dependent and had normal white blood cell and platelet counts. Nephropathologic diagnoses for the anemic ESRD patients at the time of study included chronic glomerulonephritis (2) , nephrosclerosis (2) , interstitial nephritis (2), oxalate nephropathy (1), and tuberous sclerosis (1); three patients were anephric. The three non-anemic ESRD patients included two with polycystic renal disease and one with chronic glomerulonephritis. Two control groups were studied: (1) 10 healthy individuals and (2) 5 non-uremic patients with chronic anemia (hematocrit 21 to 29%) comparable in severity to the anemic ESRD patients. Diagnoses in this latter group included paroxysmal nocturnal hemoglobinuria (2), sickle cell disease (2) , and pyruvate kinase deficiency (I). These studies were two hours at room temperature and then centrifuged at 2000 g for 15 minutes. The serum was centrifuged a second time and the supernatant removed. Aliquots were frozen and stored at -70° for later determination of Epo levels. For 8 of the anemic ESRD patients and 6 of the healthy controls, the remaining serum was sterilized by passage through a 0.45 micron Millipore filter (Millipore Corporation, Bedford, Massachusetts, USA), heat-inactivated at 56° for 30 minutes, and frozen and stored at 70° until assayed for inhibitory activity in autologous marrow cell culture studies. To prepare plasma, the blood was drawn into plastic syringes containing 10 U/mI preservative-free heparin (O'Neal, Jones, and Feldman, St. Louis, Missouri, USA) and centrifuged at 2000 g for 15 minutes. The plasma was centrifuged a second time, the supernatant withdrawn and sterilized by passage through a 0.45 micron Millipore filter, and frozen and stored at -70° until assayed for inhibitors in marrow culture studies.
Bone marrow samples
Bone marrow samples were aspirated from the posterior iliac crest into plastic syringes containing 250 units of preservativefree heparin and diluted to a final volume of 20 ml in Hanks' balanced salt solution (Gibco, Grand Island, New York, USA). Low-density mononuclear cells were isolated by density centrifugation on Ficoll-diatrizoate (1.077 g/ml; LSMR, Litton Bionetics, Kensington, Maryland, USA) as previously described [6] . The cells were suspended to a final concentration of 106/ml in alpha medium (Gibco) supplemented with 10% heatinactivated fetal calf serum (FCS, HyClone, Logan, Utah, USA). Twenty ml volumes of the cell suspension were incubated for two hours in 75 cm2 plastic tissue culture flasks (Corning Glass Works, Corning, New York, USA) at 37° in 5% CO2 in air and the non-adherent cells were harvested for use in colony-forming assays.
Colony-f hrming assays Hematopoietic colony-forming cells were assayed in methylcellulose culture by previously described methods [6] [7] [8] . Erythroid colony-forming cells were assayed by culturing non-adherent marrow cells at a concentration of l05/ml in alpha medium made semisolid with 1% methylcellulose and supplemented with 1% deionized bovine serum albumin (Sigma Chemical Company, St Louis, Missouri, USA), 1 mro l-glutaniine (Gibco), 1O M beta-mercaptoethanol, penicillin-streptomycin, 5% phytohemagglutinin-stimulated peripheral blood leukocyte-conditioned medium (PHA-LCM) [6] , and I V/mi human urinary Epo. One ml volumes were cultured in 35 mm plastic tissue culture dishes (LuxR, Miles Laboratories, Naperville, Illinois, USA) at 37° in 5% CO2 in air. Erythroid colonies (derived from CFU-E) and bursts (from BFU-E) were enumerated after 7 and 13 days in culture, respectively, with an inverted microscope. Aggregates of 8 or more hemoglobinized cells were scored as CFU-E-derived colonies. Erythroid bursts were identified as colonies of at least 200 hemoglobinized cells or as aggregates of two or more hemoglobinized subcolonies, Granulocyte-macrophage and megakaryocyte colony-forming cells (CFU-GM and CFU-Meg, respectively) were assayed by culturing non-adherent marrow cells at a concentration of 105/ml in Iscove's modified Dulbecco medium (Gibco) made semisolid with 0.9% methylcellulose and supplemented with 25% normal human plasma (from a single lot), 1 ms'i l-glutamine, 5 >< 10 M beta-mercaptoethanol, penicillin-streptomycin, and 5% PHA-LCM. One ml volumes were cultured for 13 days as above and granulocyte-macrophage and megakaryocyte colonies enumerated. Granulocyte-macrophage colonies were identified by inverted microscopy as aggregates of 40 or more cells. Megakaryocyte colonies were identified as aggregates of four or more cells with characteristic refractile cell membranes and translucent agranular cytoplasm [6] .
Epo
The Epo used in these studies was partially purified from the urine of a patient with pure red cell aplasia, as previously described [9, 101. The final preparation had a specific activity of approximately 500 units per mg protein and, in control experiments, supported only the growth of erythroid colonies or bursts.
Assays for hematopoietic inhibitory and stimulatory activities in serum or plasma The capacity of ESRD patient (N 8) and control (N = 6) serum or plasma to support or inhibit colony formation was examined by observing the effect of several concentrations of serum or plasma on colony growth from autologous marrow cells. CFU-E-and BFU-E-derived colony growth in the presence of 5, 10, or 15% test serum plus 15% FCS was compared to colony growth in the presence of the same total concentration of FCS alone [10] . In these studies, a suboptimal concentration of Epo (0.3 U/mI) that gave 70% of maximal erythroid colony and burst growth was used. The capacity of the test serum to support (or inhibit) erythroid colony growth was expressed as percent control colony growth [ two patients with ESRD had serum Epo levels which exceeded the upper limit of the normal range. However, the mean values of the ESRD and control groups did not differ significantly (P> 0. I). Five patients with chronic anemia and intact renal function had serum Epo levels that were significantly higher than normal. We found no correlation between serum Epo levels and hematocrit or erythroid progenitor frequency in any of the study groups (data not shown). Erythroid progenitors, as they mature, become increasingly responsive to Epo in terms of their proliferative activity [12] . Therefore, we speculated that the relative proportions of primitive and late erythroid precursor cells should reflect Epo levels in vivo. Accordingly, we exaniined the ratio of CFU-E frequency to BFU-E frequency for each of the ESRD and control groups. As we also observed with their serum Epo levels (Table 1), the healthy controls and ESRD patients did not differ significantly in their CFU-E/BFU-E ratios (Fig. 2) . However, the non-uremic anemic patients that we studied had CFU-E/BFU-E ratios that were significantly increased (P <0.001) in comparison to the normal controls and ESRD patients (Fig. 2) . In none of the patient or control groups was there a significant correlation between serum Epo levels and CFU-E/BFU-E ratios.
We examined the effect of pre-dialysis anemic ESRD and normal control serum and plasma on colony growth from autologous marrow cells. As shown in Table 2 , normal and ESRD sera and plasma were equally supportive of erythroid and non-erythroid colony growth. We did not observe inhibition. None of the mean values shown differed significantly from control colony growth (P > 0.1). Likewise, there were no significant differences in colony growth (expressed as control) at any of the serum or plasma concentrations tested (P > 0.1). There was no correlation between the Epo concentrations of individual serum samples and their capacity to support CFU-E-or BFU-E-derived colony growth (not shown).
Discussion
The anemia which almost always accompanies ESRD is a consequence of diminished red blood cell production [1, 2] . In this study, we have utilized in vitro colony-forming assays to examine hematopoietic progenitor cell frequencies in anemic and non-anemic ESRD patients and healthy controls. Nonerythroid as well as erythroid colony-forming cells were assayed to determine the lineage specificity of any observed changes from normal. In order to investigate how the erythroid progenitor cell response in vivo might be influenced by Epo levels, we correlated serum Epo levels, measured by RIA, with erythroid progenitor cell frequencies.
We found no significant differences between the anemic ESRD, non-anemic ESRD, and normal control groups in the frequencies of BFU-E, CFU-E, CFU-GM, or CFU-Meg (Fig.  1 ). Likewise, we found no significant differences between these groups in their mean serum Epo levels, although several ESRD patients had values above or below the normal range (Table 1) .
Similar findings with respect to serum Epo levels in uremic patients have been reported by others [18, 19] .
Because the chronic stimulation of endogenous Epo production in experimental models of anemia results in an increase in the numbers of CFU-E but not BFU-E [20] , we reasoned that the relative numbers of late and primitive erythroid progenitors should reflect Epo levels in vivo. Therefore, we determined CFU-E/BFU-E ratios in our ESRD patients and healthy controls and correlated these ratios with serum Epo levels. Mean CFU-E/BFU-E ratios of the ESRD patients and normal controls were not significantly different (Fig. 2) . In contrast, a group of non-uremic anemic patients with elevated serum Epo levels (Table I) had CFU-E/BFU-E ratios that were significantly greater than the ESRD and healthy control groups (Fig.  2) . We found no correlation between CFU-E/BFU-E ratios and serum Epo levels in either patient group or the normal control group.
Two sets of clinical observations suggest that retained uremic inhibitors may contribute to the impaired erythropoietic response observed in ESRD. First, the institution of chronic dialysis may be associated with a gradual increase in hemoglobin concentration without effecting an increase in serum Epo levels [21, 22] . Second, some anemic ESRD patients have serum Epo levels, measured by RIA or bioassay, that are higher than normal [18, 19, 22, 231 . Some of our data indirectly support the existence of uremic inhibitors. We observed two uremic patients, one anemic and the other non-anemic, with elevated serum Epo levels (137 and 51 mU/mI, respectively) but normal CFU-E/BFU-E ratios (1.55 and 1.28, respectively). Since we did not perform simultaneous measurements of Epo levels by bioassay in these patients, the possibility that our RIA was detecting immunoreactive but not bioactive Epo cannot be excluded. However, the sera from these patients did not inhibit autologous erythroid colony formation in vitro (see below). The observed decline in erythroid colony growth from marrow cells cultured in the presence of either whole uremic serum or candidate uremic toxins has been cited as evidence supporting a pathogenetic role for retained inhibitors [19, [23] [24] [25] [26] . However, such studies are compromised by flaws in design. First, they failed to examine non-erythroid colony growth concurrently to determine the specificity of potential erythropoietic inhibitors. The issue of specificity is important since leukopenia or thrombocytopenia is seldom seen in anemic ESRD patients. In fact, we have found that granulocytemacrophage and megakaryocyte colony growth from mouse marrow cells are as sensitive as erythroid colony formation to the inhibitory effects of uremic serum and the candidate uremic toxins spermine and spermidine [8, 101 . Second, several studies fail to show that the observed reduction in colony growth in the presence of uremic serum reflects the presence of inhibitors rather than a lack of stimulatory factors. Finally, many studies used heterologous or xenogeneic marrow targets. Interpretation of the results of such studies might be confounded by the influence of serum alloantibodies and potentially non-physiological interactions between serum factors and marrow cells from different species.
In this study, we have assayed uremic serum and plasma for erythropoietic inhibitors using autologous marrow cells as target. We examined erythroid and non-erythroid colony growth concurrently to define the lineage-specificity of any observed effect. Test sera or plasmas were added to cultures containing suboptimal concentrations of Epo and FCS or normal plasma. This strategy permitted the identification of stimulatory as well as inhibitory effects of test serum and plasma on colony growth [101. Utilizing this protocol which avoids the shortcomings of previous studies, we found no evidence for inhibitors of in vitro hematopolesis in uremic serum and plasma. Pre-dialysis serum and plasma from anemic ESRD patients were as supportive of autologous erythroid and non-erythroid colony growth as serum and plasma from healthy controls and non-anemic ESRD patients ( Table 2 ). It is possible that this result reflects loss of inhibitory activity with filtration, heat-inactivation, and/or freezing of the test samples. This explanation would appear unlikely since we and others have consistently observed inhibition of murine colony formation by uremic sera subjected to these same treatments [10, 19, . Finally, we observed no relationship between the Epo concentrations of individual serum samples and their capacity to support CFU-E-or BFU-Ederived colony growth (not shown). Careful in vivo studies provide no evidence for the existence of retained inhibitors of erythroid marrow function. Sheep rendered uremic, anemic, and dialysis-dependent displayed the same erythropoietic response to infused Epo-rich sheep plasma as they did when they were normal [27] . We conclude that the relative numbers of erythroid and non-erythroid colony-forming cells are unchanged from normal in patients with the anemia of ESRD. The normal CFU-E/BFU-E ratio observed in these patients reflects an inadequate compensatory erythropoietic response due to their inability to increase Epo production to levels appropriate to their degree of anemia. Although a few of these patients had elevated serum Epo levels, we did not detect inhibitors of autologous hematopoietic colony formation in uremic serum or plasma. Retained inhibitors might still play a role in the development of the anemia of ESRD, but definitive proof of their existence and pathogenetic significance will require in vivo Epo challenge studies in normal and uremic subjects.
